cd47 peptide Overexpression of CD47 enables cancer cells to escape phagocytosis - Minimal self peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles is a transmembrane protein The Emerging Role of CD47 Peptides in Cancer Immunotherapy

Cd47 peptidecloaked lipid nanoparticles promote cell specific mrna delivery The intricate dance between cancer cells and the immune system is a complex area of ongoing research. One critical player in this interaction is CD47, a transmembrane protein also known as integrin-associated protein (IAP).作者：B Mustafa·2023·被引用次数：2—The discovered anti-CD47 peptidescan be considered potential candidates for cancer immunotherapyby blocking the CD47/SIRPα interaction, ... CD47 is ubiquitously present and plays a crucial role in regulating cellular interactions. When CD47 is overexpressed on tumor cells, it acts as a potent "don't eat me" signal, effectively cloaking them from immune surveillance and contributing to immune escape. This phenomenon hinders the ability of macrophages to recognize and engulf cancerous cells, a process known as phagocytosisCD47 (Cluster of Differentiation 47) also known as integrin associated protein (IAP)is a transmembrane protein that in humans is encoded by the CD47 gene..

Recent scientific advancements have focused on developing innovative therapeutic strategies that target the CD47 signaling pathway to re-engage the immune system against cancer. Among these, CD47 peptide-based therapeutics are emerging as a promising avenue. These peptides are designed to specifically interact with CD47 or its receptor, SIRPα, thereby blocking the inhibitory signal and enhancing anti-tumor immunity.作者：B Mustafa·2023·被引用次数：2—The discovered anti-CD47 peptidescan be considered potential candidates for cancer immunotherapyby blocking the CD47/SIRPα interaction, ...

Mechanistic Insights into CD47 Peptides

The interaction between CD47 and its receptor, SIRP$\alpha$, is central to the "don't eat me" signalCD47 peptide-cloaked lipid nanoparticles promote .... Researchers have identified various peptides that can disrupt this crucial bindingCD47 (Cluster of Differentiation 47) also known as integrin associated protein (IAP)is a transmembrane proteinthat in humans is encoded by the CD47 gene.. For instance, studies have explored the development of CD47 peptide-cloaked lipid nanoparticles (LNPs). These LNPs, when modified with a CD47 peptide that mimics the "don't eat me" signal, can actually reduce uptake by macrophages and liver cells in vitro and in vivo. This might seem counterintuitive, but the strategy lies in using these modified LNPs as delivery vehicles for therapeutics, where the CD47 peptide influences their biodistribution and targeting.

Furthermore, research has demonstrated that CD47 modification can decrease macrophage and hepatic uptake, a finding that is critical for optimizing drug delivery systems. Advances in protein engineering have led to the creation of synthetic peptides designed to block the CD47/SIRP$\alpha$ interaction. Some of these peptides, such as the 21-amino-acid peptide derived from the C-terminal domain of thrombospondin-1, have shown efficacy in efficiently killing malignant CLL B cells.Blocking CD47 with restructured peptide nanoparticles for ... The identification of novel CD47-blocking peptides, such as VK17, through techniques like phage display, exemplifies the ongoing efforts in this field.

Therapeutic Applications and Future Directions

The ability of CD47 peptides to disrupt the CD47/SIRP$\alpha$ pathway makes them potential candidates for cancer immunotherapy. By blocking this interaction, peptides can enhance the phagocytic ability of macrophages, thereby promoting tumor destruction. For example, CD47 blocking peptides can be incorporated into nanoparticles作者：AC Martinez-Torres·2015·被引用次数：98—The targeting of CD47 with peptides derived from the C-terminal domain of thrombospondin-1efficiently kills the malignant CLL B cells.. PAP NPs (Peptide-Antibody-Peptide Nanoparticles), for instance, can self-assemble to form fibrous networks and anchor CD47 on the surface of tumor cells, promoting their recognition and phagocytosis by macrophages.

The CD47/SIRP$\alpha$ pathway is considered a new breakthrough in tumor immunity, comparable to the PD-1/PD-L1 axis.作者：B Mustafa·2023·被引用次数：2—The discovered anti-CD47 peptidescan be considered potential candidates for cancer immunotherapyby blocking the CD47/SIRPα interaction, ... While monoclonal antibody therapies targeting CD47 have shown promise, peptides offer potential advantages, including smaller size, better tissue penetration, and potentially lower manufacturing costs.

In the context of cancer immunotherapy, researchers are exploring various peptide-based strategiesAn antitumor peptide RS17‐targeted CD47, design .... This includes the design of macrocyclic peptides that bind to SIRP$\alpha$ and block its interaction with CD47.作者：TE Papp·2025·被引用次数：19—This study describes apeptide-cloaked LNP-mRNA platform that incorporates a “don't eat me”CD47signal into LNP-mRNA. This modification ... Another innovative approach involves creating chimeric peptides for dual blockade. For instance, a novel CD47-blocking peptide VK17 was fused to a pro-apoptotic peptide (VK30) to achieve synergistic effects作者：Y Xia·2022·被引用次数：4—PAP NPs can self-assemble to form fibrous networks and anchor CD47on the surface of tumor cells, promoting their recognition and phagocytosis by macrophages..

The search intent behind the keyword "cd47 peptide" clearly indicates a strong interest in these therapeutic applications. Users are looking for information on how these peptides function, their role in enhancing macrophage activity (such as when PAC-SABI enhances the phagocytic ability of macrophages), and their potential as therapeutic agents.Definition of magrolimab - NCI Drug Dictionary - National Cancer Institute The fact that CD47 is found to be overexpressed on tumor cells and that CD47 expressed on tumor cells protects them from phagocytosis are key drivers for this research.

Beyond direct targeting, CD47 peptides can be utilized in drug delivery systems. For instance, peptide-functionalized lipid nanoparticles are being explored for targeted systemic mRNA delivery to the brainAn antitumor peptide RS17‐targeted CD47, design .... Moreover, CD47 peptide-albumin cloaked mesoporous silica nanoparticles are being investigated for their selectivity towards macrophage cells.

The scientific community continues to explore novel peptides with specific anti-tumor properties作者：B Li·2023·被引用次数：7—CD47/SIRPα pathwayis a new breakthrough in the field of tumor immunity after PD-1/PD-L1. While current monoclonal antibody therapies .... Research into macrocyclic peptide-mediated blockade of the CD47/SIRP$\alpha$ interaction and the discovery of anti-CD47 peptides as innate immune enhancers highlight the diverse approaches being taken. The development of a synthetic peptide designed for use in combination with anti-CD47 antibodies further underscores the multifaceted nature of peptide involvement in tumor immunology.CD47:Has a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. Plays an important role in ... Ultimately, the goal is to harness the power of peptides to overcome immune evasion mechanisms employed by cancer and to pave the way for improved therapeutic outcomes.